Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis
D. CHIANELLI, Paul V. Rucker, Jason Roland, David C. Tully, John T. Nelson, Xiaodong Liu, Badry Bursulaya, Eloy D. Hernandez, Jane Y. Wu, Mahavir Prashad, Thierry Schlama, Yugang Liu, Alan Chu, James Schmeits, David Huang, Robert Hill, Dingjiu Bao, Jocelyn Zoll, Young Kim, Todd Groessl, Peter McNamara, Bo Liu, Wendy Richmond, Ignacio Sancho-Martinez, Andrew Phimister, H. Martin Seidel, Michael K. Badman, Sean B. Joseph, Bryan Laffitte, Valentina Molteni
Abstract
. Nidufexor has advanced to Phase 2 human clinical trials in patients with NASH and diabetic nephropathy.
Topics & Concepts
Farnesoid X receptorObeticholic acidBile acidChemistrySteatohepatitisAgonistPharmacologyG protein-coupled bile acid receptorPartial agonistChenodeoxycholic acidInternal medicineNonalcoholic fatty liver diseaseNuclear receptorEndocrinologyMedicineReceptorFatty liverBiochemistryDiseaseTranscription factorGeneLiver Disease Diagnosis and TreatmentDrug Transport and Resistance MechanismsLiver Diseases and Immunity